Prodrugs and codrugs as strategies for improving percutaneous absorption

References

• Nanayakkara GR, Bartlett A, Forbes B, Marriott C, Whitfield PJ, Brown MB. The effect of unsaturated fatty acids in benzyl alcohol on the percutaneous permeation of three model penetrants. Int. J. Pharm.301(1–2), 129–139 (2005).
   PubMed Web of Science ®Google Scholar
• Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog. Lipid Res.42(1), 1–36 (2003).
   PubMed Web of Science ®Google Scholar
• Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skin – theory and in vitro experimental measurement. AIChE J.21(5), 985–996 (1975).
   Web of Science ®Google Scholar
• Elias PM, Cooper ER, Korc A, Brown BE. Percutaneous transport in relation to stratum corneum structure and lipid composition. J. Invest. Dermatol.76(4), 297–301 (1981).
   PubMed Web of Science ®Google Scholar
• Foldvari M. Non-invasive administration of drugs through the skin: challenges in delivery system design. Pharm. Sci. Technol. Today3(12), 417–425 (2000).
   PubMedGoogle Scholar
• Hadgraft J, Valenta C. PH, pK(a) and dermal delivery. Int. J. Pharm.200(2), 243–247 (2000).
   PubMed Web of Science ®Google Scholar
• Wilkes GL, Brown IA, Wildnauer RH. The biomechanical properties of skin. CRC Crit. Rev. Bioeng.1(4), 453–495 (1973).
   PubMedGoogle Scholar
• Guy RH, Hadgraft J. Transdermal Drug Delivery. Marcel Dekker Inc., NY, USA (2003).
   Google Scholar
• Cross SE, Roberts MS. Subcutaneous absorption kinetics and local tissue distribution of interferon and other solutes. J. Pharm. Pharmacol.45(7), 606–609 (1993).
   PubMed Web of Science ®Google Scholar
• Bonina FP, Puglia C, Barbuzzi T et al.In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur. J. Pharm. Sci.14(2), 123–134 (2001).
   PubMed Web of Science ®Google Scholar
• Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci.14(2), 101–114 (2001).
   PubMed Web of Science ®Google Scholar
• Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J. Variations of hair follicle size and distribution in different body sites. J. Invest. Dermatol.122(1), 14–19 (2004).
   PubMed Web of Science ®Google Scholar
• Scheuplein RJ. Mechanism of percutaneous absorption. 2. Transient diffusion and relative importance of various routes of skin penetration. J. Invest. Dermatol.48(1), 79–88 (1967).
   PubMed Web of Science ®Google Scholar
• Wertz PW, Downing DT. Stratum Corneum: biological and biochemical considerations. In: Transdermal Drug Delivery: Development Issues and Research Initiatives. Hadgraft J, Guy RH (Eds). Marcel Dekker, NY, USA 1–22 (1989)
   Google Scholar
• Elias PM, Brown BE, Fritsch P, Goerke J, Gray GM, White RJ. Localization and composition of lipids in neonatal mouse stratum granulosum and stratum-corneum. J. Invest. Dermatol.73(5), 339–348 (1979).
   PubMed Web of Science ®Google Scholar
• Williams A. Transdermal and Topical Drug Delivery: From Theory to Clinical Practice. Pharmaceutical Press, London, UK (2003).
   Google Scholar
• Kydonieus AF, Berner B (Eds). Transdermal Delivery of Drugs. CRC Press, Boca Raton, FL, USA (1987).
   Google Scholar
• Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm. Res.12(10), 1526–1529 (1995).
   PubMed Web of Science ®Google Scholar
• Brown L, Langer R. Transdermal delivery of drugs. Annu. Rev. Med.39, 221–229 (1988).
   PubMed Web of Science ®Google Scholar
• Singh BN, Singh RB, Singh J. Effects of ionization and penetration enhancers on the transdermal delivery of 5-fluorouracil through excised human stratum corneum. Int. J. Pharm.298(1), 98–107 (2005).
   PubMed Web of Science ®Google Scholar
• du Plessis J, Pugh WJ, Judefeind A, Hadgraft J. Physico–chemical determinants of dermal drug delivery: effects of the number and substitution pattern of polar groups. Eur. J. Pharm. Sci.16(3), 107–112 (2002).
   PubMed Web of Science ®Google Scholar
• Li GL, Van Steeg TJ, Putter H et al. Cutaneous side-effects of transdermal iontophoresis with and without surfactant pretreatment: a single-blinded, randomized controlled trial. Br. J. Dermatol.153(2), 404–412 (2005).
   PubMed Web of Science ®Google Scholar
• Kanikkannan N, Singh M. Skin permeation enhancement effect and skin irritation of saturated fatty alcohols. Int. J. Pharm.248(1–2), 219–228 (2002).
   PubMed Web of Science ®Google Scholar
• Chan SY, Po ALW. Prodrugs for dermal delivery. Int. J. Pharm.55(1), 1–16 (1989).
   Web of Science ®Google Scholar
• Stinchcomb AL, Swaan PW, Ekabo O et al. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin. J. Pharm. Sci.91(12), 2571–2578 (2002).
   PubMed Web of Science ®Google Scholar
• Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat. Rev. Drug Discov.2(2), 132–139 (2003).
   PubMed Web of Science ®Google Scholar
• Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci.19(1), 26–37 (1998).
   PubMed Web of Science ®Google Scholar
• Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem.47(10), 2393–2404 (2004).
   PubMed Web of Science ®Google Scholar
• Li C, Nguyen V, Johnson P et al.The Study of Transdermal Administration of Ace Inhibitors and Improved Absorption of Their Prodrugs. Noven Pharmaceuticals Inc., Miami, FL, USA (2000).
   Google Scholar
• Leppanen J, Huuskonen J, Nevalainen T, Gynther J, Taipale H, Jarvinen T. Design and synthesis of a novel l-dopa-entacapone codrug. J. Med. Chem.45(6), 1379–1382 (2002).
   PubMed Web of Science ®Google Scholar
• Yang CS, Khawly JA, Hainsworth DP et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol.116(1), 69–77 (1998).
   PubMed Web of Science ®Google Scholar
• Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-β-naltrexol via a codrug linked to hydroxybupropion. J. Control. Release113(2), 137–145 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Chow M. Prednicarbate (Dermatop): profile of a corticosteroid. J. Cutan. Med. Surg.8(4), 244–247 (2004).
   PubMedGoogle Scholar
• Bodor N. Designing safer drugs based on the soft drug approach. Trends Pharmacol. Sci.3(2), 53–56 (1982).
   Web of Science ®Google Scholar
• Bodor N, Sloan KB, Little RJ, Selk SH, Caldwell L. Soft drugs . 4. 3-spirothiazolidines of hydrocortisone and its derivatives. Int. J. Pharm.10(4), 307–321 (1982).
   Google Scholar
• Kligman AM, Kaidbey KH. Hydrocortisone revisited – historical and experimental evaluation. Cutis22(2), 232–234 (1978).
   PubMed Web of Science ®Google Scholar
• Reitamo S, Rustin M, Ruzicka T et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J. Allergy Clin. Immunol.109(3), 547–555 (2002).
   PubMed Web of Science ®Google Scholar
• Jacob SE, Steele T. Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J. Am. Acad. Dermatol.54(4), 723–727 (2006).
   PubMed Web of Science ®Google Scholar
• Parneix-Spake A, Goustas P, Green R. Eumovate (clobetasone butyrate) 0.05% cream with its moisturizing emollient base has better healing properties than hydrocortisone 1% cream: a study in nickel-induced contact dermatitis. J. Dermatolog. Treat.12(4), 191–197 (2001).
   PubMed Web of Science ®Google Scholar
• Fowler JF, Fransway AF, Jackson JM, Rohowsky N. Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis. Cutis75(2), 125–131 (2005).
   PubMedGoogle Scholar
• Lipp R, Laurent H, Gunther C, Riedl J, Esperling P, Tauber U. Prodrugs of gestodene for matrix-type transdermal drug delivery systems. Pharm. Res.15(9), 1419–1424 (1998).
   PubMed Web of Science ®Google Scholar
• Heger-Mahn D, Warlimont C, Faustmann T, Gerlinger C, Klipping C. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. Eur. J. Contracept. Reprod. Health Care9(3), 173–181 (2004).
   PubMed Web of Science ®Google Scholar
• Evans JMM, McGregor E, McMahon AD et al. Nonsteroidal antiinflammatory drugs and hospitalization for acute-renal-failure. QJM88(8), 551–557 (1995).
   PubMed Web of Science ®Google Scholar
• Rautio J, Nevalainen T, Taipale H et al. Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (naproxen) for topical drug delivery. J. Med. Chem.43(8), 1489–1494 (2000).
   PubMed Web of Science ®Google Scholar
• Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem. Toxicol.33(12), 1061–1080 (1995).
   PubMed Web of Science ®Google Scholar
• Montenegro L, Carbone C, Maniscalco C et al.In vitro evaluation of quercetin-3-O-acyl esters as topical prodrugs. Int. J. Pharm.336(2), 257–262 (2007).
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Alterman AI, Hayashida M, Obrien CP. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry49(11), 876–880 (1992).
   PubMed Web of Science ®Google Scholar
• Medical E. PDR Generics. Thomson Healthcare, Montvale, NJ, USA (1996).
   Google Scholar
• Pillai O, Hamad MO, Crooks PA, Stinchcomb AL. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm. Res.21(7), 1146–1152 (2004).
   PubMed Web of Science ®Google Scholar
• Beall HD, Sloan KB. Transdermal delivery of 5-fluorouracil (5-FU) by 1-alkylcarbonyl-5-FU prodrugs. Int. J. Pharm.129(1–2), 203–210 (1996).
   Web of Science ®Google Scholar
• Hammell DC, Hamad M, Vaddi HK, Crooks PA, Stinchcomb AL. A duplex ‘Gemini’ prodrug of naltrexone for transdermal delivery. J. Control. Release97(2), 283–290 (2004).
   PubMed Web of Science ®Google Scholar
• Alexander J, Cargill R, Michelson SR, Schwam H. (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines – increased permeation through biological-membranes. J. Med. Chem.31(2), 318–322 (1988).
   PubMed Web of Science ®Google Scholar
• Vaddi HK, Banks SL, Chen J et al.Human Skin Permeation of 3-O Alkyl Carbamate Prodrugs of Naltrexone. University of Kentucky, KY, USA (2007).
   Google Scholar
• Otagiri M, Imai T, Fukuhara A. Improving the pharmacokinetic and pharmacodynamic properties of a drug by chemical conversion to a chimera drug. J. Control. Release62(1–2), 223–229 (1999).
   PubMed Web of Science ®Google Scholar
• Ackerley N, Brewster AG, Brown GR et al. A novel-approach to dual-acting thromboxane receptor antagonist and synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and 1,3-dioxane-thromboxane synthase inhibitors. J. Med. Chem.38(10), 1608–1628 (1995).
   PubMed Web of Science ®Google Scholar
• Cynkowska G, Cynkowski T, Al-Ghananeem AA, Guo H, Ashton P, Crooks PA. Novel antiglaucoma prodrugs and codrugs of ethacrynic acid. Bioorg. Med. Chem. Lett.15(15), 3524–3527 (2005).
   PubMed Web of Science ®Google Scholar
• Bryskier A. Dual β-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment. Expert Opin. Investig. Drugs6(10), 1479–1499 (1997).
   PubMedGoogle Scholar
• Hayford KE, Patten CA, Rummans TA et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br. J. Psychiatry174, 173–178 (1999).
   PubMed Web of Science ®Google Scholar
• Scheuplein RJ, Blank IH. Permeability of the skin. Physiol. Rev.51(4), 702–747 (1971).
   PubMed Web of Science ®Google Scholar
• Lluria-PrevattIn: Fundamentals of Cancer Prevention. Alberts DS, Hess LM (Eds). Springer, NY, USA 161–201 (2005).
   Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer3(5), 330–338 (2003).
   PubMed Web of Science ®Google Scholar
• Sloan KB, Sherertz EF, Mctiernan RG. The effect of structure of mannich base prodrugs on their ability to deliver theophylline and 5-fluorouracil through hairless mouse skin. Int. J. Pharm.44(1–3), 87–96 (1988).
   Google Scholar
• Sherertz EF, Sloan KB, McTiernan RG. Transdermal delivery of 5-fluorouracil through skin of hairless mice and humans in vitro – a comparison of the effect of formulations and a prodrug. Arch. Dermatol. Res.282(7), 463–468 (1990).
   PubMed Web of Science ®Google Scholar
• Beall H, Prankerd R, Sloan K. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkyloxycarbonyl-5-FU prodrugs – physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm.111(3), 223–233 (1994).
   Web of Science ®Google Scholar
• Suppasansatorn P, Nimmannit U, Conway BR, Du LR, Wang YF. Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE). J. Pharm. Pharmacol.59(6), 787–794 (2007).
   PubMed Web of Science ®Google Scholar
• Suppasansatorn P, Wang G, Conway BR, Wang W, Wang Y. Skin delivery potency and antitumor activities of temozolomide ester prodrugs. Cancer Lett.244(1), 42–52 (2006).
   PubMed Web of Science ®Google Scholar
• Mukai E, Arase K, Hashida M, Sezaki H. Enhanced delivery of mitomycin-C prodrugs through the skin. Int. J. Pharm.25(1), 95–103 (1985).
   Google Scholar
• Jacobson EL, Antol KM, Juarezsalinas H, Jacobson MK. Poly(ADP-ribose) metabolism in ultraviolet irradiated human-fibroblasts. J. Biol. Chem.258(1), 103–107 (1983).
   PubMed Web of Science ®Google Scholar
• Kim H, Jacobson M, Kim M, Jacobson E, Qasem J. A topical niacin prodrug enhances wound healing by stimulation of leptin secretion. J. Invest. Dermatol.119(1), 347–347 (2002).
   Google Scholar
• Jacobson EL, Kim H, Kim M, Wondrak GT, Jacobson MK. Developing topical prodrugs for skin cancer prevention. In: Fundamentals of Cancer Prevention. Alberts DS, Hess LM (Eds). Springer, NY, USA 139–160 (2005).
   Google Scholar